6.83
-1.21 (-15.05%)
| Previous Close | 8.04 |
| Open | 7.85 |
| Volume | 328,686 |
| Avg. Volume (3M) | 657,316 |
| Market Cap | 371,601,856 |
| Price / Book | 2.10 |
| 52 Weeks Range | |
| Earnings Date | 19 Mar 2025 |
| Diluted EPS (TTM) | -10.38 |
| Total Debt/Equity (MRQ) | 11.81% |
| Current Ratio (MRQ) | 6.01 |
| Operating Cash Flow (TTM) | -255.08 M |
| Levered Free Cash Flow (TTM) | -150.41 M |
| Return on Assets (TTM) | -87.31% |
| Return on Equity (TTM) | -198.66% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Alumis Inc. | Bearish | - |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | 4.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.40 |
|
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 1.21% |
| % Held by Institutions | 85.41% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ayurmaya Capital Management Company, Lp | 31 Dec 2024 | 10,645,966 |
| Foresite Capital Management V, Llc | 31 Dec 2024 | 5,779,348 |
| Venbio Partners Llc | 31 Dec 2024 | 2,787,398 |
| Omega Fund Management, Llc | 31 Dec 2024 | 653,223 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 32.00 (Oppenheimer, 368.52%) | Buy |
| Median | 23.50 (244.07%) | |
| Low | 15.00 (HC Wainwright & Co., 119.62%) | Buy |
| Average | 23.50 (244.07%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 5.82 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 26 Mar 2025 | 15.00 (119.62%) | Buy | 4.92 |
| 20 Mar 2025 | 15.00 (119.62%) | Buy | 3.57 | |
| Oppenheimer | 30 Jan 2025 | 32.00 (368.52%) | Buy | 6.72 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BABLER MARTIN | 7.24 | - | 15,650 | 113,306 |
| COLOWICK ALAN | 8.54 | - | 18,404 | 139,225 |
| Aggregate Net Quantity | 34,054 | |||
| Aggregate Net Value ($) | 252,531 | |||
| Aggregate Avg. Buy ($) | 8.11 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| COLOWICK ALAN | Director | 02 Apr 2025 | Buy (+) | 2,300 | 9.84 | 22,632 |
| BABLER MARTIN | Officer | 01 Apr 2025 | Buy (+) | 15,650 | 7.24 | 113,306 |
| COLOWICK ALAN | Director | 01 Apr 2025 | Buy (+) | 16,104 | 7.24 | 116,593 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |